表紙
市場調查報告書

亞太地區的生物製程設施(2020年)

Asia-Pacific Bioprocessing Facilities Report 2020

出版商 IMAPAC PTE. LTD 商品編碼 941253
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
亞太地區的生物製程設施(2020年) Asia-Pacific Bioprocessing Facilities Report 2020
出版日期: 2020年04月20日內容資訊: 英文 300 Pages
簡介

本報告提供亞太地區的生物製程設施的相關調查,提供法規和核准,設施規模,財務的洞察,各地區的生物製程設施的資料等資訊。

目錄

章節(型材)

  • 序文
  • 調查範圍和資料的範圍
  • IMAPAC的調查手法

第2章 大中華圈的生物製程設施

  • Henlius Pharma
  • Innovent Biologics
  • Pfizer
  • Tonhua Dongbao
  • AlphaMab
  • Akeso Pharmaceuticals
  • Hanmi Pharma
  • Sinovac
  • BeiGene
  • Junshi Biosciences
  • Tot Biopharma
  • Hualan Biological Engineering

第3章 韓國和日本的生物製程設施

  • Samsung Bioepis
  • Astellas
  • Celltrion
  • 中外製藥株式會社
  • Hanmi Pharma
  • 協和麒麟株式會社
  • Aprogen Biologiccs
  • 第一三共株式會社

第4章 印度和澳洲的生物製程設施

  • Aurobindo
  • CSL Bering
  • Serum Institute of India
  • CSIRO
  • Enzene Biosciences
  • Stelis Biopharma

第5章 東南亞的生物製程設施

  • Abbvie
  • GSK
  • AJ Biologics
  • Amgen
  • Novartis Thailand
  • Baxter
  • 武田藥品工業株式會社
  • Siam Biosciences

第6章 每個地區的資料和生產設施分析(對象地區:中國,台灣,日本,韓國,印度,澳洲,海)

  • 所製造的產品:疫苗·細胞療法·重組蛋白質及單株抗體·其他
  • 收納技術·生物流程
  • 廠房容量
  • 開發平台(管線)的計劃
  • 生物製造投資
  • 法規·核准
  • 設施規模,設計
  • 財務的洞察
  • PESTEL分析

第7章 其他

  • 參考文獻
  • 免責聲明
  • 本公司關於
  • 其他報告
目錄

The Biologics industry is evolving at an unprecedented rate by demanding for new and improved technologies to reduce cost and increase efficiency. The world is seeing an increase in Biopharma facilities, especially in Asia to meet the growing demands of biologic drugs. Yet, the number one factor reported to cause capacity constraints at bioprocessing facilities in the near future is facility constraints.

Hence, IMAPAC has put together a comprehensive report on 65+ Bioprocessing facilities in the past ten years that have been constructed in the Asia- Pacific region including countries such as China, India, Korea, Japan, SEA, Australia. This report will provide detailed analysis from their manufacturing capabilities, Process Technologies to key details on their Facility Construction Design. We will be providing information straight from our interaction with top players in the industry and key management of companies, on how their facilities provide them with the flexibility to expand their manufacturing capabilities while cutting cost.

Are you also looking to expand your operations to meet the growing global demands? If you would like to learn from the successful players in the industry and not repeat the same mistakes as some of your competitors, check out the full report now.

Table of Contents

Section 1

  • Preface
  • Report Scope & Data Coverage
  • IMAPAC's Research Methodology

Section 2: Bioprocessing Facilities in Greater China

  • Henlius Pharma
  • Innovent Biologics
  • Pfizer
  • Tonhua Dongbao
  • AlphaMab
  • Akeso Pharmaceuticals
  • Hanmi Pharma
  • Sinovac
  • BeiGene
  • Junshi Biosciences
  • Tot Biopharma
  • Hualan Biological Engineering

Section 3: Bioprocessing Facilities In Korea And Japan

  • Samsung Bioepis
  • Astellas
  • Celltrion
  • Chugai
  • Hanmi Pharma
  • Kyowa Hakko Kirin
  • Aprogen Biologiccs
  • Daiichi Sankyo

Section 4: Bioprocessing Facilities In India And Australia

  • Aurobindo
  • CSL Bering
  • Serum Institute of India
  • CSIRO
  • Enzene Biosciences
  • Stelis Biopharma

Section 5: Bioprocessing Facilities In South-East-Asia

  • Abbvie
  • GSK
  • AJ Biologics
  • Amgen
  • Novartis Thailand
  • Baxter
  • Takeda
  • Siam Biosciences

Section 6: Region-Wise Data & Analysis Of Manufacturing Facility {Regions Covered: China, Taiwan, Japan& Korea, India, Australia & Sea}

  • Products Manufactured: Vaccines - Cell Therapy - Recombinant Proteins & Mabs - Others
  • Technologies Housed and Bioprocessing Processes
  • Plant Capacity
  • Projects In Pipeline
  • Biomanufacturing Investment
  • Regulatory Approvals
  • Facility Size, Design
  • Financial Insights
  • Pestel Analysis

Section 7: Our Other Reports

  • Bibiliography
  • Disclaimer
  • About Us
  • Our Other Reports

List Of Tables

Summary Of Manufacturing Facilities

  • Table 1: List of Top 50 Manufacturing Facilities Across Asia Pacific Covered In The Report
  • Table 2: Plant Capacity
  • Table 3: Projects Completed Thus far
  • Table 4: Financial Insights

Region Wise Analysis

China, Taiwan, India Korea, Japan, Australia, Sea

  • Table 5: Investment of Manufacturing Facilities in Greater China
  • Table 6: Investment of Manufacturing Facilities in SEA
  • Table 7: Investment of Manufacturing Facilities in Korea
  • Table 8: Bioprocessing tools, technologies and solutions in Greater China
  • Table 9: Bioprocessing tools, technologies and solutions in Japan
  • Table 10: Bioprocessing tools, technologies and solutions in Korea
  • Table 11: Facility Size and Design in Greater China
  • Table 12: Facility Size and Design in Korea
  • Table 13: Facility Size and Design in Japan
  • Table 14: Checklist for facility of the future in Greater China
  • Table 15: Checklist for facility of the future in Korea
  • Table 16: Checklist for facility of the future in Japan
  • Table 17: Product-Wise segregation for facilities in Greater China
  • Table 18: Product-Wise segregation for facilities in Korea
  • Table 19: Product-Wise segregation for facilities in Japan

List Of Figures

Regions Covered In Asia

  • Figure 1: Top 50 Bioprocessing Manufacturing Facilities from all the Asian Regions

China

  • Figure 2: Investment of Manufacturing Facility
  • Figure 3: Year of Operation
  • Figure 4: Distribution of Single- Use Bioreactors over the years
  • Figure 5: Size of the Facility
  • Figure 6: Manufacturing projects in Pipeline
  • Figure 7: Team Distribution (Manufacturing: Non-Manufacturing)

Taiwan

  • Figure 8: Investment of Manufacturing Facility
  • Figure 9: Year of Operation
  • Figure 10: Distribution of Single- Use Bioreactors over the years
  • Figure 11: Size of the Facility
  • Figure 12: Manufacturing projects in Pipeline
  • Figure 13: Team Distribution (Manufacturing: Non-Manufacturing)

Korea & Japan

  • Figure 14: Investment of Manufacturing Facility
  • Figure 15: Year of Operation
  • Figure 16: Distribution of Single- Use Bioreactors over the years
  • Figure 17: Size of the Facility
  • Figure 18: Manufacturing projects in Pipeline
  • Figure 19: Team Distribution (Manufacturing: Non-Manufacturing)

Japan

  • Figure 20: Investment of Manufacturing Facility
  • Figure 21: Year of Operation
  • Figure 22: Distribution of Single- Use Bioreactors over the years
  • Figure 23: Size of the Facility
  • Figure 24: Manufacturing projects in Pipeline
  • Figure 25: Team Distribution (Manufacturing: Non-Manufacturing)

India

  • Figure 26: Investment of Manufacturing Facility
  • Figure 27: Year of Operation
  • Figure 28: Distribution of Single- Use Bioreactors over the years
  • Figure 29: Size of the Facility
  • Figure 30: Manufacturing projects in Pipeline
  • Figure 31: Team Distribution (Manufacturing: Non-Manufacturing)